The Pilot and Feasibility Program supports young investigators beginning their careers in CF research, as well as providing the opportunity for more seasoned investigators to explore new avenues of research. Additionally, the program offers an enticement for investigators who may have an expertise of interest to CF, but without support to initiate research in CF. As a recent change to processing pilot and feasibility applications, the institutional CTSA has agreed to add the CF Pilot and Feasibility to its

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK027651-29
Application #
8320612
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (J1))
Project Start
1997-04-23
Project End
2015-03-31
Budget Start
2012-05-08
Budget End
2013-03-31
Support Year
29
Fiscal Year
2012
Total Cost
$125,577
Indirect Cost
$45,598
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Dasenbrook, Elliott C; Konstan, Michael W; VanDevanter, Donald R (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14:370-5
Than, B L N; Goos, J A C M; Sarver, A L et al. (2014) The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 33:3861-8
Xu, Weiling; Janocha, Allison J; Leahy, Rachel A et al. (2014) A novel method for pulmonary research: assessment of bioenergetic function at the air-liquid interface. Redox Biol 2:513-9
Boyle, Michael P; Bell, Scott C; Konstan, Michael W et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:527-38
Doring, Gerd; Bragonzi, Alessandra; Paroni, Moira et al. (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13:156-63
Spilker, Theodore; Leber, Amy L; Marcon, Mario J et al. (2014) A simplified sequence-based identification scheme for Bordetella reveals several putative novel species. J Clin Microbiol 52:674-7
Zaman, Khalequz; Bennett, Deric; Fraser-Butler, Maya et al. (2014) S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface. Biochem Biophys Res Commun 443:1257-62
VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2014) Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. J Pediatr 165:1091-1097.e2
Caretti, Anna; Bragonzi, Alessandra; Facchini, Marcella et al. (2014) Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. Biochim Biophys Acta 1840:586-94
Kerem, Eitan; Konstan, Michael W; De Boeck, Kris et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2:539-47

Showing the most recent 10 out of 274 publications